~~<i id='A92C67A06A'><strike id='A92C67A06A'><tt id='A92C67A06A'><pre id='A92C67A06A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：knowledge 2025-08-23 06:54:07 - browse：43

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： CommonSpirit Health keeps growing, even as it loses money

explore

focus

hotspot

explore

Thematchstick-sized,implantabledevicefromIntarciaTherapeuticsreleasesasteady,continuous,andlow-doses

WSS

Medicare Advantage enrollment hits roughly 33.4 million

Surprise medical billing ban raises prices elsewhere

In 'major milestone,' FDA approves first cell therapy for solid tumors

Hospitals are piloting generative AI tools as regulators play catch

It's been 20 years since Dolly the sheep. Where's my clone?

Experts study whether long Covid risk adds up with each reinfection

leisure time

entertainment

explore

How to save PrEP access — and even expand it

Opioid cravings were reduced by anti

Novavax promises a turnaround & Lilly roils the obesity market

Experts study whether long Covid risk adds up with each reinfection

Novavax promises a turnaround & Lilly roils the obesity market

Emergency workers more likely to restrain Black patients: study

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Moonlake's readout produced a cash windfall. Risks remain

Reporting on presidential health from Reagan to Trump and Biden

explore

Biotech stock slump in 2023: awaiting the turnaround

As AI regulations shape up, health tech startups beg for clarity

As AI regulations shape up, health tech startups beg for clarity

Abridge raises $150m as clinical notes automation market heats up

Researchers tackle phage therapy hurdles for wider adoption

Drug for rare kidney disease narrowly misses mark in clinical trial

explore

focus

hotspot

explore